Sanofi cancer drug deal with Avila worth up to $800M

Mon, 12/20/2010 - 3:37am
Mass High Tech: The Journal of New England Technology

Avila Therapeutics Inc., a privately held biotechnology company, will receive an upfront payment of $40 million from French drug maker sanofi-aventis, as part of a research collaboration aimed at developing cancer drugs that could net it a total of $800 million.

The Waltham-based biotech will also receive up to $154 million in milestone payments per program for any drug that is eventually approved from a total of six separate development programs, and could also receive royalty payments if a treatment reaches the market.

The announcement underscores sanofi’s growing interest in acquiring and partnering with Massachusetts biotechnology companies, at it seeks to strengthen its position in biologics - cell-based drugs - versus pharmaceuticals, made from chemicals. Sanofi is locked in a four month long stalemate with Cambridge-based Genzyme Corp. (Nasdaq:GENZ), following an acquisition offer of $69 per share of Genzyme stock, with Genzyme says is too low. Sanofi revealed last week that less that one percent of Genzyme’s shares had been tendered so far.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.